Neuropeptide Y polymorphism increases the risk for asthma in overweight subjects; protection from atherosclerosis in asthmatic subjects - The cardiovascular risk in young Finns study

Neuropeptides

Volumn 46, Issue 6, 2012, Pages 321-328

  Jaakkola, U ^a   Kakko, T ^a   Juonala, M ^a   Lehtimaki T ^b   Viikari, J ^a   Jaaskelainen A E ^a   Mononen, N ^b   Kahonen M ^c   Koskinen, T ^a   Keltikangas Jarvinen L ^d   Raitakari, O ^a,e   Kallio, J ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Asthma; Atheroscrerosis; Autonomic nervous system; Neuropeptide Y; Polymorphism

Indexed keywords

NEUROPEPTIDE Y;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; FEMALE; FINLAND; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART RATE VARIABILITY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ALLELES; ANTHROPOMETRY; ASTHMA; ATHEROSCLEROSIS; BODY HEIGHT; BODY WEIGHT; CAROTID INTIMA-MEDIA THICKNESS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DNA; ENDOTHELIUM, VASCULAR; FEMALE; FINLAND; GENE FREQUENCY; GENOTYPE; HEART RATE; HUMANS; LIPIDS; MALE; NEUROPEPTIDE Y; OVERWEIGHT; POLYMORPHISM, GENETIC; RISK;

EID: 84869864087     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.09.005     Document Type: Article

References (62)

1. Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J. Diabetes Complications 2000, 14:154-174.
2. Bedoui S., Kuhlmann S., Nave H., Drube J., Pabst R., von Horsten S. Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J. Neuroimmunol. 2001, 117:125-132.
3. Bischoff A., Michel M.C. Renal effects of neuropeptide Y. Pflugers Arch. 1998, 435:443-453.
4. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., Lloyd J.K., Deanfield J.E. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
5. Clarke J.G., Davies G.J., Kerwin R., Hackett D., Larkin S., Dawbarn D., Lee Y., Bloom S.R., Yacoub M., Maseri A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987, 1:1057-1059.
6. de Koning L., Merchant A.T., Pogue J., Anand S.S. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur. Heart J. 2007, 28:850-856. 10.1093/eurheartj/ehm026.
7. de Simone G., Devereux R.B., Chinali M., Best L.G., Lee E.T., Galloway J.M., Resnick H.E., Strong Heart Study Investigators Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care 2007, 30:1851-1856. 10.2337/dc06-2152.
8. Eaton K., Sallee F.R., Sah R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem. 2007, 7:1645-1659.
9. Eller N.H., Malmberg B., Bruhn P. Heart rate variability and intima media thickness. Int. J. Behav. Med. 2006, 13:201-213. 10.1207/s15327558ijbm1303_3.
10. Finn P.W., Bigby T.D. Innate immunity and asthma. Proc. Am. Thorac. Soc. 2009, 6:260-265. 10.1513/pats.200807-064RM.
11. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
12. Gold D.R., Damokosh A.I., Dockery D.W., Berkey C.S. Body-mass index as a predictor of incident asthma in a prospective cohort of children. Pediatr. Pulmonol. 2003, 36:514-521. 10.1002/ppul.10376.
13. Groneberg D.A., Folkerts G., Peiser C., Chung K.F., Fischer A. Neuropeptide Y (NPY). Pulm. Pharmacol. Ther. 2004, 17:173-180. 10.1016/j.pupt.2004.04.003.
14. Hansson G.K. Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost. 2009, 7(Suppl 1):328-331. 10.1111/j.1538-7836.2009.03416.x.
15. Husemoen L.L., Glumer C., Lau C., Pisinger C., Morch L.S., Linneberg A. Association of obesity and insulin resistance with asthma and aeroallergen sensitization. Allergy 2008, 63:575-582. 10.1111/j.1398-9995.2007.01613.x.
16. Jaakkola U., Kuusela T., Jartti T., Pesonen U., Koulu M., Vahlberg T., Kallio J. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression and increased cardiovascular responsiveness to norepinephrine during oral glucose-tolerance test. J. Clin. Endocrinol. Metab. 2005, 90:3646-3652. 10.1210/jc.2005-0153.
17. Jaakkola U., Kallio J., Heine R.J., Nijpels G., T'Hart L.M., Maassen J.A., Bouter L.M., Stehouwer C.D., Dekker J.M. Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study. Eur. J. Clin. Nutr. 2009, 63:150-152. 10.1038/sj.ejcn.1602964.
18. Jaakkola U., Kakko T., Seppala H., Vainio-Jylha E., Vahlberg T., Raitakari O.T., Kallio J. The Leu7Pro polymorphism of the signal peptide of neuropeptide Y (NPY) gene is associated with increased levels of inflammatory markers preceding vascular complications in patients with type 2 diabetes. Microvasc. Res. 2010, 80:433-439. 10.1016/j.mvr.2010.07.010.
19. Jartti T. Asthma, asthma medication and autonomic nervous system dysfunction. Clin. Physiol. 2001, 21:260-269.
20. Jartti T.T., Tahvanainen K.U., Kaila T.J., Kuusela T.A., Koivikko A.S., Vanto T.T., Valimaki I.A. Cardiovascular autonomic regulation in asthmatic children evidenced by spectral analysis of heart rate and blood pressure variability. Scand. J. Clin. Lab. Invest. 1996, 56:545-554.
21. Juonala M., Viikari J.S., Laitinen T., Marniemi J., Helenius H., Ronnemaa T., Raitakari O.T. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 2004, 110:2918-2923. 10.1161/01.CIR.0000147540.88559.00.
22. Kakko T., Jaakkola U., Raitakari O.T., Kallio J. Inflammatory effects of blood leukocytes: association with vascular function in neuropeptide Y proline 7-genotyped type 2 diabetes patients. Diab. Vasc. Dis. Res. 2011, 8:221-228. 10.1177/1479164111415882;10.1177/1479164111415882.
23. Kallio J., Pesonen U., Kaipio K., Karvonen M.K., Jaakkola U., Heinonen O.J., Uusitupa M.I., Koulu M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 2001, 15:1242-1244.
24. Kallio J., Pesonen U., Jaakkola U., Karvonen M.K., Helenius H., Koulu M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J. Clin. Endocrinol. Metab. 2003, 88:3278-3283.
25. Karvonen M.K., Pesonen U., Koulu M., Niskanen L., Laakso M., Rissanen A., Dekker J.M., Hart L.M., Valve R., Uusitupa M.I. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 1998, 4:1434-1437. 10.1038/4027 [doi].
26. Karvonen M.K., Valkonen V.P., Lakka T.A., Salonen R., Koulu M., Pesonen U., Tuomainen T.P., Kauhanen J., Nyyssonen K., Lakka H.M., Uusitupa M.I., Salonen J.T. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001, 159:145-151. doi: S0021915001004683.
27. Kataoka M., Ito C., Sasaki H., Yamane K., Kohno N. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res. Clin. Pract. 2004, 64:51-58. 10.1016/j.diabres.2003.10.009.
28. Kim N.S., Oh S.M., Ko M.M., Cha M.H., Kang B.K., Bang O.S. Association of the C-399T promoter polymorphism of neuropeptide Y with susceptibility to ischemic stroke. Clin. Biochem. 2009, 42:1699-1704. 10.1016/j.clinbiochem.2009.07.012.
29. Knoflach M., Kiechl S., Mayr A., Willeit J., Poewe W., Wick G. Allergic rhinitis, asthma, and atherosclerosis in the Bruneck and ARMY studies. Arch. Intern. Med. 2005, 165:2521-2526. 10.1001/archinte.165.21.2521.
30. Koskinen T., Kahonen M., Jula A., Mattsson N., Laitinen T., Keltikangas-Jarvinen L., Viikari J., Valimaki I., Ronnemaa T., Raitakari O.T. Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular risk in young Finns study. Diabet. Med. 2009, 26:354-361. 10.1111/j.1464-5491.2009.02686.x.
31. Kuo L.E., Abe K., Zukowska Z. Stress, NPY and vascular remodeling: Implications for stress-related diseases. Peptides 2007, 28:435-440. 10.1016/j.peptides.2006.08.035.
32. Levite M. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc. Natl. Acad. Sci. USA 1998, 95:12544-12549. 10.1073/pnas.95.21.12550.
33. Liao D., Carnethon M., Evans G.W., Cascio W.E., Heiss G. Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes 2002, 51:3524-3531.
34. Lombardi F. Clinical implications of present physiological understanding of HRV components. Card. Electrophysiol. Rev. 2002, 6:245-249.
35. Mai X.M., Nilsson L., Axelson O., Braback L., Sandin A., Kjellman N.I., Bjorksten B. High body mass index, asthma and allergy in Swedish schoolchildren participating in the International Study of Asthma and Allergies in Childhood: Phase II. Acta Paediatr. 2003, 92:1144-1148.
36. Mitchell G.C., Wang Q., Ramamoorthy P., Whim M.D. A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y. J. Neurosci. 2008, 28:14428-14434. 10.1523/JNEUROSCI.0343-08.2008.
37. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76-79.
38. Morgan D.G., Kulkarni R.N., Hurley J.D., Wang Z.L., Wang R.M., Ghatei M.A., Karlsen A.E., Bloom S.R., Smith D.M. Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 1998, 41:1482-1491.
39. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737. 10.1038/nri3073.
40. Nilsson T., Lind H., Brunkvall J., Edvinsson L. Vasodilation in human subcutaneous arteries induced by neuropeptide Y is mediated by neuropeptide Y Y1 receptors and is nitric oxide dependent. Can. J. Physiol. Pharmacol. 2000, 78:251-255.
41. Niskanen L., Voutilainen-Kaunisto R., Terasvirta M., Karvonen M.K., Valve R., Pesonen U., Laakso M., Uusitupa M.I., Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2000, 108:235-236.
42. Onufrak S., Abramson J., Vaccarino V. Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study. Atherosclerosis 2007, 195:129-137. 10.1016/j.atherosclerosis.2006.09.004.
43. Otsuki M., Miyatake A., Fujita K., Hamasaki T., Kasayama S. Reduced carotid atherosclerosis in asthmatic patients treated with inhaled corticosteroids. Eur. Respir. J. 2010, 36:503-508. 10.1183/09031936.00090009.
44. Pedrazzini T., Pralong F., Grouzmann E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 2003, 60:350-377.
45. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., Eckel R.H. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 2006, 26:968-976. 10.1161/01.ATV.0000216787.85457.f3.
46. Prod'homme T., Weber M.S., Steinman L., Zamvil S.S. A neuropeptide in immune-mediated inflammation, Y?. Trends Immunol. 2006, 27:164-167. 10.1016/j.it.2006.02.003.
47. Raitakari O.T., Juonala M., Kahonen M., Taittonen L., Laitinen T., Maki-Torkko N., Jarvisalo M.J., Uhari M., Jokinen E., Ronnemaa T., Akerblom H.K., Viikari J.S. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the cardiovascular risk in young Finns study. JAMA 2003, 290:2277-2283. 10.1001/jama.290.17.2277.
48. Raitakari O.T., Juonala M., Ronnemaa T., Keltikangas-Jarvinen L., Rasanen L., Pietikainen M., Hutri-Kahonen N., Taittonen L., Jokinen E., Marniemi J., Jula A., Telama R., Kahonen M., Lehtimaki T., Akerblom H.K., Viikari J.S. Cohort profile: the cardiovascular risk in young Finns study. Int. J. Epidemiol. 2008, 37:1220-1226. 10.1093/ije/dym225.
49. Ronmark E., Andersson C., Nystrom L., Forsberg B., Jarvholm B., Lundback B. Obesity increases the risk of incident asthma among adults. Eur. Respir. J. 2005, 25:282-288. 10.1183/09031936.05.00054304.
50. Schanen J.G., Iribarren C., Shahar E., Punjabi N.M., Rich S.S., Sorlie P.D., Folsom A.R. Asthma and incident cardiovascular disease: the atherosclerosis risk in communities study. Thorax 2005, 60:633-638.
51. Shah P.K., Lakhotia M., Mehta S., Jain S.K., Gupta G.L. Clinical dysautonomia in patients with bronchial asthma. Study with seven autonomic function tests. Chest 1990, 98:1408-1413.
52. Shah S.H., Freedman N.J., Zhang L., Crosslin D.R., Stone D.H., Haynes C., Johnson J., Nelson S., Wang L., Connelly J.J., Muehlbauer M., Ginsburg G.S., Crossman D.C., Jones C.J., Vance J., Sketch M.H., Granger C.B., Newgard C.B., Gregory S.G., Goldschmidt-Clermont P.J., Kraus W.E., Hauser E.R. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet. 2009, 5:e1000318. 10.1371/journal.pgen.1000318.
53. Skibola D.R., Smith M.T., Bracci P.M., Hubbard A.E., Agana L., Chi S., Holly E.A. Polymorphisms in ghrelin and neuropeptide Y genes are associated with non-Hodgkin lymphoma. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1251-1256. 10.1158/1055-9965.EPI-04-0895.
54. Thomsen S.F., Ulrik C.S., Kyvik K.O., Sorensen T.I., Posthuma D., Skadhauge L.R., Steffensen I., Backer V. Association between obesity and asthma in a twin cohort. Allergy 2007, 62:1199-1204. 10.1111/j.1398-9995.2007.01480.x.
55. Umetsu D.T., DeKruyff R.H. The regulation of allergy and asthma. Immunol. Rev. 2006, 212:238-255. 10.1111/j.0105-2896.2006.00413.x.
56. Wallerstedt S.M., Skrtic S., Eriksson A.L., Ohlsson C., Hedner T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J. Hypertens. 2004, 22:1277-1281.
57. Wheway J., Herzog H., Mackay F. NPY and receptors in immune and inflammatory diseases. Curr. Top. Med. Chem. 2007, 7:1743-1752.
58. Yu J.T., Yu N.N., Gao S.S., Song J.H., Ma T., Wang N.D., Tang Y.C., Zhang N., Tan L. Neuropeptide Y polymorphisms and ischemic stroke in Chinese population. Clin. Chim. Acta 2010, 411:242-245. 10.1016/j.cca.2009.11.011.
59. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452:997-1001. 10.1038/nature06858.
60. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann. N. Y. Acad. Sci. 1995, 771:219-233.
61. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., Yeh Y., Chen W.T., Kleinman H.K., Grouzmann E., Grant D.S. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 1998, 83:187-195.
62. Zureik M., Kony S., Neukirch C., Courbon D., Leynaert B., Vervloet D., Ducimetiere P., Neukirch F. Bronchial hyperresponsiveness to methacholine is associated with increased common carotid intima-media thickness in men. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1098-1103. 10.1161/01.ATV.0000128128.65312.05.